Dtsch Med Wochenschr 2016; 141(16): 1167-1169
DOI: 10.1055/s-0042-106732
Klinischer Fortschritt
Verdauungs- und Stoffwechselerkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Therapieoptionen bei (schweren) gastrointestinalen Blutungen

Recent therapeutic options of (severe) gastrointestinal bleedings
Georg Braun
1   III. Medizinische Klinik, Klinikum Augsburg
,
Andreas Probst
1   III. Medizinische Klinik, Klinikum Augsburg
,
Helmut Messmann
1   III. Medizinische Klinik, Klinikum Augsburg
› Author Affiliations
Further Information

Publication History

Publication Date:
10 August 2016 (online)

    Permissions and Reprints

Zusammenfassung

Mit Idarucizumab steht erstmals ein spezifisches Antidot zur Antagonisierung der Dabigatran-Wirkung bei schwerer Blutungskomplikation unter direkten oralen Antikoagulanzien (DOAK) zur Verfügung. In der endoskopischen Therapie schwerer gastrointestinaler Blutungen finden topisch aufzutragende Substanzen und neue Hämostase-Clips Beachtung in den neu erschienenen Leitlinien. Besonders bei rezidivierenden Ulkusblutungen können die neu entwickelten Clips eine Hämostase erreichen und eine Operation verhindern. Bei Patienten mit koronarer Herzkrankheit sollte ein liberaleres Transfusionsregime angewendet werden.

Abstract

With Idarucizumab, a specific antidote to antagonize the effect of dabigatran, is now available in severe bleeding complications under directly oral anticoagulants (DOAC). In endoscopic treatment of severe gastrointestinal bleeding are alternative treatment options also available with hemostasis sprays and new hemostasis clips. Especially in recurrent ulcer bleedings, the newly developed clips can achieve hemostasis and prevent an operational procedure. In patients with coronary heart disease, a liberal transfusion regimen should be considered.

Schlüsselwörter

direkte orale Antikoagulanzien - Idarucizumab - Hämostase-Sprays - OTSC® - Transfusionsregime

Keywords

non-vitamin-K oral anticoagulants - Idarucizumab - hemostasis sprays - OTSC® - blood transfusion regimen
 

  • Literatur

  • 1 Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
    CrossrefPubMedGoogle Scholar
  • 2 van Es N, Coppens M, Schulman S et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975
    CrossrefPubMedGoogle Scholar
  • 3 Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis 2013; 2013: 640-723
    Google Scholar
  • 4 Abraham NS, Singh S, Alexander GC et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015; 350: h1857
    CrossrefPubMedGoogle Scholar
  • 5 Lip GY, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and / or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-3179
    CrossrefGoogle Scholar
  • 6 Braun G, Messmann H, Labenz J et al. [Direct oral anticoagulation and gastrointestinal bleeding: Interventional therapy management]. Med Klin Intensivmed Notfmed 2015; 110: 510-514
    CrossrefGoogle Scholar
  • 7 Pollack Jr. CV, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520
    CrossrefPubMedGoogle Scholar
  • 8 Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 2015; ohne Seitenzahl, DOI: 10.1093/europace/euv030.
    Google Scholar
  • 9 Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373: 2413-2424
    CrossrefPubMedGoogle Scholar
  • 10 Gralnek IM, Dumonceau JM, Kuipers EJ et al. Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: a1-46
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Denzer U, Beilenhoff U, Eickhoff A et al. [S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021–022]. Z Gastroenterol 2015; 53: 1496-1530
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015; 47: 167-171
    Article in Thieme ConnectGoogle Scholar
  • 13 Nagata N, Niikura R, Sakurai T et al. Safety and Effectiveness of Early Colonoscopy in Management of Acute Lower Gastrointestinal Bleeding on the Basis of Propensity Score Matching Analysis. Clin Gastroenterol Hepatol 2016; 14: 558-564
    CrossrefPubMedGoogle Scholar
  • 14 Villanueva C, Colomo A, Bosch A et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 11-21
    CrossrefPubMedGoogle Scholar
  • 15 Jairath V, Kahan BC, Gray A et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015; 386: 137-144
    CrossrefGoogle Scholar